A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

A Randomized, Parallel, Single-Center, Double-Masked, Vehicle-Controlled Phase II Study to Evaluate the Activity of NS2 Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Provocation Test (CAPT)

This is a randomized, parallel, single center, double masked, vehicle controlled study. The purpose of this study is to determine the activity and safety of NS2 in patients with grass, tree or ragweed-pollen induced seasonal allergic conjunctivitis . Subjects will be randomized 1:1 to receive multiple doses of NS2 Ophthalmic Drops (0.5%) or NS2 Ophthalmic Drops Vehicle (0.0%).

Free aldehydes are thought to be related to inflammatory conditions such as allergic conjunctivitis. NS2, a small molecule aldehyde trap, is being evaluated to determine whether it may decrease inflammation by lowering aldehyde levels.

Study Overview

• Status: Completed
• Conditions: Allergic Conjunctivitis; Seasonal Allergies
• Intervention / Treatment: Drug: NS2 Ophthalmic Drops (0.5%); Drug: NS2 Ophthalmic Drops Vehicle (0.0%)

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Mississauga, Ontario, Canada, L4W 1A4
      • Inflamax Research Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Graded conjunctival redness in at least one region (nasal or temporal) in each eye at any one time point (not necessarily the same time point) post-CAPT (Conjunctival Allergen Provocation Test) of >2
• Graded ocular itching at any one time point
• Visual acuity of at least 20/50 in each eye
• At least 2 year history of moderate to severe allergic conjunctivitis.
• Positive skin prick test to ragweed, grass and/or tree pollen within one year of Screening Visit (Visit 1).
• Ability to avoid any topical or systemic ocular medications during the entire study period.

Exclusion Criteria:

• Subjects must not have an ocular itching score >0 or a conjunctival redness score >1 prior to CAPT in either eye in any region (nasal or temporal) at Visits 2-4. I
• History of glaucoma, or Intraocular Pressure (IOP) over 25mmHg at the screening visit, or a history of elevated IOP within the past 1 year.
• Ocular surgery, including laser procedures, within the past 12 months of Visit 1.
• Use of glaucoma medications, antibiotics, antivirals, or topical cyclosporine within 1 month of the screening visit.
• History of dry eye syndrome, blepharitis, herpes simplex keratitis or herpes zoster keratitis.
• History of uveitis in the past 3 years.
• Presence of any ocular infection or active ocular inflammation (e.g. follicular conjunctivitis, allergic conjunctivitis) within 14 days prior to start of study (Visit 1).
• History of moderate to severe asthma or allergy induced asthma to the allergen that will be used in CAPT.
• Use of oral corticosteroids within 30 days of screening and throughout the study period; use of intranasal or inhaled corticosteroids within 14 days of screening and throughout the study period.
• Use of antihistamines (ocular, nasal, topical or oral) within 7 days prior to screening (Visit 1) and throughout the study period. Non-medicated artificial tears are allowed up to 72 hours before screening (Visit 1) and throughout the study period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NS2 Ophthalmic Drops (0.5%)	Drug: NS2 Ophthalmic Drops (0.5%)
Sham Comparator: NS2 Ophthalmic Drops Vehicle (0.0%); NS2 Ophthalmic Drops Vehicle (0.0%) control	Drug: NS2 Ophthalmic Drops Vehicle (0.0%)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge	Mean change from baseline in ocular itching score using a 0 to 4 scale (0 = none, 4 = severe) on Day 14, 60 minutes into the allergen challenge. The least squares mean (standard error) was derived from analysis of covariance (ANCOVA) with baseline as a covariate and treatment group as a factor.	The efficacy assessment period was assessed at Day 14; baseline was Day -7.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cytokine expression.	Mean change from baseline in cytokine expression.	Day 37 (V3), Day 44 (V3b), Day 37 (V3), Day 44 (V3b)

Collaborators and Investigators

• Sponsor: Aldeyra Therapeutics, Inc.
• Investigators: Principal Investigator: Peter Couroux, Inflamax Research Incorporated

Study record dates

Study Major Dates

• Study Start: August 1, 2015
• Primary Completion (Actual): December 1, 2015
• Study Completion (Actual): December 1, 2015

Study Registration Dates

• First Submitted: October 8, 2015
• First Submitted That Met QC Criteria: October 15, 2015
• First Posted (Estimated): October 19, 2015

Study Record Updates

• Last Update Posted (Estimated): December 5, 2023
• Last Update Submitted That Met QC Criteria: February 27, 2023
• Last Verified: May 1, 2016

More Information

Terms related to this study

• Keywords: NS2; Aldeyra; allergic conjunctivitis; seasonal allergies; ragweed allergy; grass allergy; tree allergy
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Hypersensitivity, Immediate; Eye Diseases; Otorhinolaryngologic Diseases; Respiratory Hypersensitivity; Nose Diseases; Conjunctival Diseases; Rhinitis, Allergic; Rhinitis; Hypersensitivity; Rhinitis, Allergic, Seasonal; Conjunctivitis; Conjunctivitis, Allergic; Pharmaceutical Solutions; Ophthalmic Solutions
• Other Study ID Numbers: ALDNS2-203-D1; 15-MO-001 (Other Identifier: Aldeyra Therapeutics Inc.)